FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079287622> ?p ?o ?g. }

• W2079287622 endingPage "44" @default.
• W2079287622 startingPage "35" @default.
• W2079287622 abstract "To determine the cost-effectiveness of pharmacologic treatments for overactive bladder (OAB) in the US.A decision model was constructed based on studies of effectiveness, adverse consequences, co-morbid conditions, and medical costs for the treatment of OAB. Treatment success was defined as no incontinence episodes for 3-7 days or 3-7 consecutive dry days. Estimates of treatment success were obtained from clinical trials and included darifenacin, fesoterodine, oxybutynin immediate release (IR), oxybutynin extended release (ER), oxybutynin topical gel, oxybutynin transdermal patch, solifenacin, tolterodine IR, tolterodine ER, trospium IR, and trospium ER. Probabilistic sensitivity analysis was conducted using Monte Carlo simulation.A total of 51 OAB studies were identified and 11 reported treatment success. Mean continence rates varied in the literature from 21.0% with trospium IR to 51.0% with solifenacin. The 95% CI for solifenacin's success rate was statistically higher than other regimens due to the higher continence rates from the clinical trials. Oxybutynin IR and oxybutynin ER were significantly less costly than other products. The product with the lowest incremental cost-effectiveness ratio (ICER) relative to oxybutynin IR was solifenacin at $1338 (± 168) per additional continent patient. The cost-effectiveness acceptability curve indicated that oxybutynin IR was the most cost-effective regimen when willingness-to-pay values were less than $10,000 per additional continent patient. Solifenacin was most cost-effective at higher willingness-to-pay values.There was broad overlap in effectiveness among the anti-muscarinic products, except solifenacin had a significantly higher continence rate. Oxybutynin IR and oxybutynin ER were significantly less costly than other anti-muscarinic regimens, and these two products have a useful role to play in the management of OAB. However, for patients unable to tolerate the lower cost products, formularies benefit from solifenacin among branded products since the cost-effectiveness acceptability curve demonstrated it was the product most likely to be cost-effective after oxybutynin IR." @default.
• W2079287622 created "2016-06-24" @default.
• W2079287622 creator A5015882459 @default.
• W2079287622 creator A5060356377 @default.
• W2079287622 creator A5067710734 @default.
• W2079287622 date "2012-10-08" @default.
• W2079287622 modified "2023-10-16" @default.
• W2079287622 title "Cost-effectiveness analysis of anti-muscarinic agents for the treatment of overactive bladder" @default.
• W2079287622 cites W1896534536 @default.
• W2079287622 cites W1965437296 @default.
• W2079287622 cites W1965460248 @default.
• W2079287622 cites W1967347194 @default.
• W2079287622 cites W1968860914 @default.
• W2079287622 cites W1973432536 @default.
• W2079287622 cites W1982223434 @default.
• W2079287622 cites W1993062994 @default.
• W2079287622 cites W2001275235 @default.
• W2079287622 cites W2002743872 @default.
• W2079287622 cites W2008079238 @default.
• W2079287622 cites W2009593049 @default.
• W2079287622 cites W2012563222 @default.
• W2079287622 cites W2012897345 @default.
• W2079287622 cites W2013908993 @default.
• W2079287622 cites W2019362433 @default.
• W2079287622 cites W2028475108 @default.
• W2079287622 cites W2033133691 @default.
• W2079287622 cites W2034782018 @default.
• W2079287622 cites W2037750235 @default.
• W2079287622 cites W2040768373 @default.
• W2079287622 cites W2043977360 @default.
• W2079287622 cites W2044943786 @default.
• W2079287622 cites W2054263301 @default.
• W2079287622 cites W2064365016 @default.
• W2079287622 cites W2066082956 @default.
• W2079287622 cites W2067886717 @default.
• W2079287622 cites W2071231390 @default.
• W2079287622 cites W2077631692 @default.
• W2079287622 cites W2081725554 @default.
• W2079287622 cites W2086940332 @default.
• W2079287622 cites W2115070503 @default.
• W2079287622 cites W2123804835 @default.
• W2079287622 cites W2131173377 @default.
• W2079287622 cites W2134585430 @default.
• W2079287622 cites W2135162196 @default.
• W2079287622 cites W2136500714 @default.
• W2079287622 cites W2138124730 @default.
• W2079287622 cites W2141398206 @default.
• W2079287622 cites W2143567846 @default.
• W2079287622 cites W2144564072 @default.
• W2079287622 cites W2145220255 @default.
• W2079287622 cites W2148524234 @default.
• W2079287622 cites W3025742837 @default.
• W2079287622 doi "https://doi.org/10.3111/13696998.2012.732635" @default.
• W2079287622 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22998646" @default.
• W2079287622 hasPublicationYear "2012" @default.
• W2079287622 type Work @default.
• W2079287622 sameAs 2079287622 @default.
• W2079287622 citedByCount "19" @default.
• W2079287622 countsByYear W20792876222013 @default.
• W2079287622 countsByYear W20792876222014 @default.
• W2079287622 countsByYear W20792876222015 @default.
• W2079287622 countsByYear W20792876222016 @default.
• W2079287622 countsByYear W20792876222018 @default.
• W2079287622 countsByYear W20792876222020 @default.
• W2079287622 countsByYear W20792876222021 @default.
• W2079287622 countsByYear W20792876222022 @default.
• W2079287622 crossrefType "journal-article" @default.
• W2079287622 hasAuthorship W2079287622A5015882459 @default.
• W2079287622 hasAuthorship W2079287622A5060356377 @default.
• W2079287622 hasAuthorship W2079287622A5067710734 @default.
• W2079287622 hasConcept C126894567 @default.
• W2079287622 hasConcept C142724271 @default.
• W2079287622 hasConcept C204787440 @default.
• W2079287622 hasConcept C2777844464 @default.
• W2079287622 hasConcept C2778531004 @default.
• W2079287622 hasConcept C2778941218 @default.
• W2079287622 hasConcept C2779502394 @default.
• W2079287622 hasConcept C2781020410 @default.
• W2079287622 hasConcept C71924100 @default.
• W2079287622 hasConceptScore W2079287622C126894567 @default.
• W2079287622 hasConceptScore W2079287622C142724271 @default.
• W2079287622 hasConceptScore W2079287622C204787440 @default.
• W2079287622 hasConceptScore W2079287622C2777844464 @default.
• W2079287622 hasConceptScore W2079287622C2778531004 @default.
• W2079287622 hasConceptScore W2079287622C2778941218 @default.
• W2079287622 hasConceptScore W2079287622C2779502394 @default.
• W2079287622 hasConceptScore W2079287622C2781020410 @default.
• W2079287622 hasConceptScore W2079287622C71924100 @default.
• W2079287622 hasIssue "sup1" @default.
• W2079287622 hasLocation W20792876221 @default.
• W2079287622 hasLocation W20792876222 @default.
• W2079287622 hasOpenAccess W2079287622 @default.
• W2079287622 hasPrimaryLocation W20792876221 @default.
• W2079287622 hasRelatedWork W104992362 @default.
• W2079287622 hasRelatedWork W1507298952 @default.
• W2079287622 hasRelatedWork W2012618608 @default.
• W2079287622 hasRelatedWork W2023936923 @default.
• W2079287622 hasRelatedWork W2061936259 @default.

• next